These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 15922928)

  • 1. New drugs for bipolar disorder?
    Creavin T
    Drug Discov Today; 2005 Jun; 10(11):743. PubMed ID: 15922928
    [No Abstract]   [Full Text] [Related]  

  • 2. Anorexigenic action of pituitary adenylate cyclase-activating polypeptide (PACAP) in the goldfish: feeding-induced changes in the expression of mRNAs for PACAP and its receptors in the brain, and locomotor response to central injection.
    Matsuda K; Maruyama K; Miura T; Uchiyama M; Shioda S
    Neurosci Lett; 2005 Sep; 386(1):9-13. PubMed ID: 15975713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary adenylate cyclase activating polypeptide reduces A-type K+ currents and caspase activity in cultured adult mouse olfactory neurons.
    Han P; Lucero MT
    Neuroscience; 2005; 134(3):745-56. PubMed ID: 16019148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental role of GnRH and PACAP in a zebrafish model.
    Sherwood NM; Wu S
    Gen Comp Endocrinol; 2005 May; 142(1-2):74-80. PubMed ID: 15862551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SIDS-like phenotype is associated with reduced respiratory chemoresponses in PACAP deficient neonatal mice.
    Cummings KJ; Pendlebury JD; Jirik FR; Sherwood NM; Wilson RJ
    Adv Exp Med Biol; 2004; 551():77-83. PubMed ID: 15602947
    [No Abstract]   [Full Text] [Related]  

  • 6. Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development.
    Borba JC; Henze IP; Silveira MS; Kubrusly RC; Gardino PF; de Mello MC; Hokoç JN; de Mello FG
    Brain Res Dev Brain Res; 2005 May; 156(2):193-201. PubMed ID: 16099306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary adenylate cyclase-activating polypeptide: localization and differential influence on isolated hearts from rats and guinea pigs.
    Chang Y; Lawson LJ; Hancock JC; Hoover DB
    Regul Pept; 2005 Jul; 129(1-3):139-46. PubMed ID: 15927709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [G protein-coupled receptors (GPCR), ligand-receptor interaction studies].
    Jasionowski M; Grzonka Z; Lankiewicz L
    Postepy Biochem; 2000; 46(1):60-72. PubMed ID: 15971378
    [No Abstract]   [Full Text] [Related]  

  • 9. Association analysis of the pituitary adenylate cyclase-activating polypeptide (PACAP/ADCYAP1) gene in bipolar disorder.
    Lohoff FW; Bloch PJ; Weller AE; Ferraro TN; Berrettini WH
    Psychiatr Genet; 2008 Apr; 18(2):53-8. PubMed ID: 18349695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gulf war syndrome and sand fly saliva.
    Jacobson RL
    Med Hypotheses; 2004; 63(5):917. PubMed ID: 15488671
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of bipolar disorder with antipsychotic medication: issues shared with schizophrenia.
    Young AH
    J Clin Psychiatry; 2007; 68 Suppl 6():24-5. PubMed ID: 17650056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Users say bi-polar drugs are 'the worst ever'.
    Ment Health Today; 2003 Jun; ():7. PubMed ID: 14635439
    [No Abstract]   [Full Text] [Related]  

  • 13. Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder.
    Nakajima S; Suzuki T; Uchida H; Watanabe K; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):160-1. PubMed ID: 19032967
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and tolerability of emerging pharmacological treatments for bipolar disorder.
    Dunner DL
    Bipolar Disord; 2005 Aug; 7(4):307-25. PubMed ID: 16026484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
    Torrent C; Amann B; Sánchez-Moreno J; Colom F; Reinares M; Comes M; Rosa AR; Scott J; Vieta E
    Acta Psychiatr Scand; 2008 Jul; 118(1):4-18. PubMed ID: 18498432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006 Nov; 67(11):e16. PubMed ID: 17201046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations.
    Scolnick EM
    Biol Psychiatry; 2006 Jun; 59(11):1039-45. PubMed ID: 16616720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
    Hashimoto R; Hashimoto H; Shintani N; Chiba S; Hattori S; Okada T; Nakajima M; Tanaka K; Kawagishi N; Nemoto K; Mori T; Ohnishi T; Noguchi H; Hori H; Suzuki T; Iwata N; Ozaki N; Nakabayashi T; Saitoh O; Kosuga A; Tatsumi M; Kamijima K; Weinberger DR; Kunugi H; Baba A
    Mol Psychiatry; 2007 Nov; 12(11):1026-32. PubMed ID: 17387318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bipolar disorder: quality of life and the impact of atypical antipsychotics.
    Vornik LA; Hirschfeld RM
    Am J Manag Care; 2005 Oct; 11(9 Suppl):S275-80. PubMed ID: 16232010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric bipolar disorder: evidence-based psychopharmacological treatments.
    Banuelos-Arzac C
    J Child Adolesc Psychiatr Nurs; 2008 May; 21(2):68. PubMed ID: 18429835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.